Pharmaceutical
Related Publications
- 1. Qualifying impurities and degradation products: Anvisa's experience and technical improvement - Maria Rodrigues (Slides)
- 1. Qualifying impurities and degradation products: Anvisa's experience and technical improvement - Maria Rodrigues (Video)
- 2. Risk assessment of potential mutagenic impurities in anti-hypertensive drug products approved in Brazil - Fernanda Waechter (Slides)
- 2. Risk assessment of potential mutagenic impurities in anti-hypertensive drug products approved in Brazil - Fernanda Waechter (Video)
- 2019 Pharmaceutical Industry and Regulators Symposium Recording - Day 1, Part 1
- 2019 Pharmaceutical Industry and Regulators Symposium Recording - Day 1, Part 2
- 2019 Pharmaceutical Industry and Regulators Symposium Recording - Day 1, Part 3
- 2019 Pharmaceutical Industry and Regulators Symposium Recording - Day 1, Part 4
- 2019 Pharmaceutical Industry and Regulators Symposium Recording - Day 2, Part 1
- 2019 Pharmaceutical Industry and Regulators Symposium Recording - Day 2, Part 3
- 2019 Pharmaceutical Industry and Regulators Symposium Recording - Day 2, Part 4
- 2020 AI/PDE Webinar -Acceptable Intake (AI) and Permitted Daily Exposure (PDE) data sharing project for pharmaceutical impurities - Recording
- 2020 AI/PDE Webinar -Acceptable Intake (AI) and Permitted Daily Exposure (PDE) data sharing project for pharmaceutical impurities - Slides
- 2020 Zeneth 8 webinar - Zeneth 8: A re-designed and improved forced degradation prediction system for organic compounds - Recording
- 2020 Zeneth 8 webinar - Zeneth 8: A re-designed and improved forced degradation prediction system for organic compounds - Slides
- 2021 Webinar - An overview of Effiris 2.1; An enhanced qualitative model suite for anticipating and mitigating adverse drug reactions – Slides and recording
- 2021 Webinar | Accessing vital sources of long-term carcinogenicity study data with Lhasa’s Carcinogenicity Database – An update and an overview - Recording
- 2021 Webinar | Accessing vital sources of long-term carcinogenicity study data with Lhasa’s Carcinogenicity Database – An update and an overview - Slides
- 3. Case studies on the qualification of impurities - Mariah Ultramari (Slides)
- 3. Case studies on the qualification of impurities - Mariah Ultramari (Video)
- A collaborative benchmarking study to evaluate the newly released Zeneth 8
- A consortium-driven framework to guide the implementation of ICH M7 Option 4 control strategies
- A defined approach for predicting skin sensitisation hazard and potency based on the guided integration of in silico, in chemico and in vitro data using exclusion criteria
- A Nitrite Excipient Database: A Useful Tool to Support N-Nitrosamine Risk Assessments for Drug Products
- A pharma-wide approach to address the genotoxicity prediction of primary aromatic amines.
- A practical application of two in silico systems for identification of potentially mutagenic impurities
- A quantitative in silico model for predicting skin sensitization using a nearest neighbours approach within expert-derived structure–activity alert spaces
- A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity
- Accessing Carcinogenicity Potency Data
- Addressing toxicity risk when designing and selecting compounds in early drug discovery
- Aiding and standardising expert review under ICH M7
- Aiding and standardising expert review under ICH M7 - Recording
- An Elemental Impurities Excipient Database: A Viable Tool for ICH Q3D Drug Product Risk Assessment
- An evaluation of in-house and off-the-shelf in silico models: Implications on guidance for mutagenicity assessment
- An Evaluation of the Occupational Health Hazards of Peptide Couplers
- An Expert System To Predict the Forced Degradation of Organic Molecules
- An in Silico Method for Predicting Ames Activities of Primary Aromatic Amines
- Anticipating and mitigating adverse drug reactions through machine learning and privacy-preserving data sharing (infographic)
- Application of adverse outcome pathways (AOPs) to support genotoxicity assessment
- Application of AOPs for Weight-of-Evidence Assessments: Rationalising Evidence for the ICH S1B(R1) Guidance Addendum
- Are All Nitrosamines Concerning?
- Are all nitrosamines concerning? A review of mutagenicity and carcinogenicity data
- Assessing confidence in predictions made by knowledge-based systems
- Assessing Confidence in Predictions.wmv
- Assessment of the dermal sensitisation potency of extractables and leachables using existing data and in silico methods
- Beyond adverse outcome pathways: making toxicity predictions from event networks, SAR models, data and knowledge
- Biotransformation Pathways of Biocides and Pharmaceuticals in Freshwater Crustaceans
- Building Secondary Pharmacology Models: A Novel Approach to Proprietary Data Transfer - Recording
- Building Secondary Pharmacology Models: A Novel Approach to Proprietary Data Transfer.
- Case study on the use of integrated approaches to testing and assessment for the prediction of a 90-day repeated dose toxicity study (OECD 408) for 2-Ethylbutyric acid using a read-across approach from other branched carboxylic acids.
- Collaborative analysis of complex nitrosamines
- Comparing and combining in silico outcomes and in vitro mechanism-based assays to predict genotoxicity
- Controlling a cohort - Understanding the risk of nitrosamines within drug substance synthesis (Webinar Presentation Slides)
- Could purge calculations support your regulatory submissions? (Infographic)
- Data Dos and Don’ts In Building Statistical Models For Ames Mutagenicity
- Data Sharing Projects using Vitic [an infographic]
- Deriving compound-specific exposure limits for chemicals used in pharmaceutical synthesis: Challenges in expert decision-making exemplified through a case study-based workshop
- Determination of compound-specific acceptable daily intakes for 11 mutagenic carcinogens used in pharmaceutical synthesis
- Developing Federated QSAR Models for Secondary Pharmacology
- Developing structure-activity relationships for N-nitrosamine activity
- Developing Structure-Activity Relationships for the Prediction of Hepatotoxicity
- Development of a network of carcinogenicity adverse outcome pathways and its employment as an evidence framework for safety assessment
- Development of an Adverse Outcome Pathway Network to Support an Integrated Approach to Testing and Assessment of Carcinogenic Risk
- Development of an Adverse Outcome Pathway Network to Support an Integrated Approach to Testing and Assessment of Carcinogenic Risk - SOT 2021 Presentation Slides
- Do all nitrosamines pose a significant level of genotoxic risk? (Webinar Presentation Slides)
- Draft Reflection Paper - Non-Genotoxic Impurities
- EC3: Methodology Explained
- Effiris_Improving in silico secondary pharmacology profiling using federated QSAR models
- eTRANSAFE: Building a sustainable framework to share reproducible drug safety knowledge with the public domain
- Evaluation Of A Statistics-based Ames Mutagenicity QSAR Model And Interpretation Of The Results Obtained
- Evaluation of the Global Performance of Eight In Silico Skin Sensitization Models Using Human Data
- Evaluation Of The Statistics-Based Ames Mutagenicity Model Sarah Nexus And Interpretation Of The Results Obtained
- Expert Review of EC3 Predictions
- Expert Systems - The Use of Expert Systems in Drug Design-Toxicity and Metabolism
- Food for thought - A toxicology ontology roadmap
- GSK MI risk assessment process Camicinal at al - 2020 ICH M7 India Roadshow
- Guidelines for FAIR sharing of preclinical safety and off-target pharmacology data
- Hazard Assessment of Potentially Mutagenic Impurities - 2020 ICH M7 India Roadshows
- How to resolve inconclusive predictions from defined approaches for skin sensitisation in OECD Guideline No. 497
- How Well Do Defined Approaches Predict the Human Skin Sensitisation Potential of Previously Untested Chemicals?
- HuskinDB, a database for skin permeation of xenobiotics
- ICH M7 - Regulatory Updates and Industry Practices - 2020 ICH M7 India Roadshows
- ICH M7 Classification Workflow
- ICH M7 Expert Review Workshop: Resolving common prediction scenarios using automated arguments in Nexus 2.3 (Webinar Presentation Slides)
- ICH M7 Overview: Predicting, Assessing, and Controlling Mutagenic Impurities from Degradation
- ICH M7 Workshop - 2020 ICH M7 India Roadshows
- ICH Q3D Drug Product Elemental Risk Assessment: The use of an elemental impurities excipients database
- Improving the predictive performance of in silico aromatic amine mutagencitiy alerts
- In silico methods combined with expert knowledge rule out mutagenic potential of pharmaceutical impurities: An industry survey
- In Silico Prediction of Genotoxicity Current Applications and Future Perspectives
- In silico prediction of N-nitrosamine degradants in APIs that possess a secondary or tertiary amine functional group
- In Silico Prediction of Pharmaceutical Degradation Pathways: A Benchmarking Study
- In silico workflow under ICH M7 - Recording
- Integrating Knowledge Of Carcinogenicity Adverse Outcome Pathways (AOPs) With Experimental Data_EMGS Data Challenge 2020
- Interrogating AOP-Wiki knowledge as a network
- Introducing the concept of virtual control groups into preclinical toxicology testing
- Introduction to ICH Q3D guidance_The move from heavy metal testing to ICH Q3D
- Introduction to the Lhasa Carcinogenicity Database
- Introduction to the Lhasa Carcinogenicity Database - Recording
- Investigation of an in vitro hepatotoxicity dataset to search for co-occurrence of signals amongst assays.
- iPiE: Intelligence-led Assessment of Pharmaceuticals in the Environment
- It’s difficult, but important, to make negative predictions
- Letter to the editor of Heliyon re: determination of dimethylamine and nitrite in pharmaceuticals by ion chromatography to assess the likelihood of nitrosamine formation
- Lhasa and the ICH M7 Guideline - 2020 ICH M7 India Roadshow
- Lhasa Expert Review Developments - 2020 ICH M7 India Roadshows
- Lhasa's Carcinogenicity Database - Recording
- Machine Learning Predicts Degree of Aromaticity from Structural Fingerprints
- Management of pharmaceutical ICH M7 (Q)SAR predictions – The impact of model updates
- Managing the risk of nitrosamine impurities
- Mirabilis Cost Saving Infographic
- Mirabilis Purge Ratio Infographic
- Mutagenicity assessment strategy for pharmaceutical intermediates to aid limit setting for occupational exposure
- Negative Predictions for Skin Sensitisation
- Nexus 2 - Improved functionality to assist in ICH M7 submission
- Nexus 2.2: An Overview of Key New Features - Sarah Nexus
- Nexus ICH M7 Expert Review Support Functionality (an infographic)
- Nitrosamine Reactivity: A Survey of Reactions and Purge Processes
- Observations on the Pharma's Industry Convergence toward Cloud
- Pathways for N-nitroso compound formation: secondary amines and beyond
- Perspectivas Regulatórias sobre a Qualificação de Produtos de Degradação e Impurezas
- Phosphite esters: a novel class of contact allergen
- Potential impurities in drug substances: Compound-specific toxicology limits for 20 synthetic reagents and by-products, and a class-specific toxicology limit for alkyl bromides
- Potentially mutagenic impurities: Analysis of structural classes and carcinogenic potencies of chemical intermediates in pharmaceutical syntheses supports alternative methods to the default TTC...
- Practical Implementation of (Q)SAR and Expert Review for Compliance with ICH M7 Guidelines
- Predicting N-Nitrosamine Activity from SAR
- Predicting the Purging of Impurities within an API Synthetic Pathway
- Predicting the safety of medicines in pregnancy: A workshop report
- Principles and procedures for handling out-of-domain and indeterminate results as part of ICH M7 recommended (Q)SAR analyses
- QSAR 2021 - leveraging data from multiple sources to build QSARs through curation and federated learning in Effiris.
- QSAR 2021 Addressing the global challenge of N-nitrosamine impurity assessment
- QSAR 2021 Is the bacterial reverse mutation assay an accurate predictor for N-nitrosamine carcinogenicity
- Quantifying the nitrosamine potency distribution
- Quantitative Analysis of In Vivo Dose-Response Data for Risk Assessment and Regulatory Decision Making - Recording
- Relationship between the mutagenicity of arylboronic acids and 11B NMR chemical shifts
- Resolving conflicting data sources to a single call in Sarah Nexus [an infographic]
- Session 1 - Building quantitative AOPs of the DARTable genome to explore risks of developmental toxicity - Recording
- Session 1 - Building quantitative AOPs of the DARTable genome to explore risks of developmental toxicity - Slides
- Session 1 - Creating a DART AOP network to enable improved decision-making during risk assessments - Recording
- Session 1 - Creating a DART AOP network to enable improved decision-making during risk assessments - Slides
- Session 2 - AOP and IATA complimentary frameworks to modernize chemical risk assessment - Recording
- Session 2 - AOP and IATA complimentary frameworks to modernize chemical risk assessment - Slides
- Session 2 - Integration of adverse outcome pathways with experimental data to support the assessment of carcinogenic risk - Recording
- Session 2 - Integration of adverse outcome pathways with experimental data to support the assessment of carcinogenic risk - Slides
- Session 3 - A pharmaceutical regulator’s view on the utility of adverse outcome pathways for carcinogenicity assessment - Recording
- Session 3 - A pharmaceutical regulator’s view on the utility of adverse outcome pathways for carcinogenicity assessment - Slides
- Session 3 - Exploiting AOPs as a framework to support ICH S1 risk assessments - Recording
- Session 3 - Exploiting AOPs as a framework to support ICH S1 risk assessments - Slides
- Session 4 - Combining knowledge and data on an AOP framework in order to take advantage of new and emerging methods In genotoxicity assessment - Recording
- Session 4 - Combining knowledge and data on an AOP framework in order to take advantage of new and emerging methods In genotoxicity assessment - Slides
- Session 4 - The growing network of genotoxicity AOPs - Recording
- Session 4 - The growing network of genotoxicityAOPs - Slides
- Setaria 1.2 Installation Guide
- Setaria 2.0 Installation Guide
- Setaria 3.0 Installation Guide
- Setaria 3.0.1 Installation Guide
- Setaria 3.0.1 Release Notes
- Setaria Product Brochure
- Structural features affecting nitrosamine carcinogenic potency
- Summation of Toxicity Data in Vitic
- Supporting Lhasa Members in a Regulatory Setting
- Supporting more scientifically driven risk assessments under ICH Q3D
- Supporting more scientifically driven risk assessments under ICH Q3D: Elemental Impurities Data Sharing_Webinar Recording
- Systematic analysis of protein targets associated with adverse events of drugs from clinical trials and postmarketing reports
- The Application of Adverse Outcome Pathways (AOPs) for Risk Assessment
- The eTRANSAFE Project on Translational Safety Assessment through Integrative Knowledge Management: Achievements and Perspectives
- The Landscape of Potential Small and Drug Substance Related Nitrosamines in Pharmaceuticals
- The Liability Load and how Lhasa Limited Focuses on Reducing it
- The Role of Expert Assessment and In Silico Predictions in Determining Genotoxic Risk of N-Nitrosamine Impurities
- Undertaking Expert Review under ICH M7 - A Practical Guide
- Updated Dermal Sensitisation Thresholds derived using an in silico expert system and an expanded Local Lymph Node Assay dataset
- Updated Dermal Sensitisation Thresholds derived using an in silico expert system and an expanded Local Lymph Node Assay dataset
- Use of Mirabilis based purge calculations to understand Nitrosamine-related risk and control strategy options
- Use of the bacterial reverse mutation assay to predict carcinogenicity of N-nitrosamines
- Using adverse outcome pathways to contextualise (Q)SAR predictions for reproductive toxicity – A case study with aromatase inhibition
- Using Data Associated with a Developmental and Reproductive Toxicity Adverse Outcome Network to Aid Safety Assessments
- Using privacy-preserving federated learning to enable pre-competitive cross-industry knowledge sharing and improve QSAR models
- Using Sarah Nexus Effectively: Intuitive Model Building and Interpreting Confidence
- Utilisation of parametric methods to improve percentile-based estimates for the carcinogenic potency of nitrosamines
- Utilising Adverse Outcome Pathways as a Framework to Organise Evidence and Support Carcinogenicity Risk Assessment
- Valsartan – Implications
- Vitic Data Sharing Benefits
- What Makes a Potent Nitrosamine? Statistical Validation of Expert-Derived Structure–Activity Relationships
- Who is using Vitic? Infographic
- Workbook: Expert Review of EC3 Predictions - a workshop
- Zeneth Member Type Infographic
